Clinical Trials Directory

Trials / Unknown

UnknownNCT05576233

• Comparison of Blood Culture Contamination Rates

Comparison of Blood Culture Contamination Rates Between the Use of Povidine Iodine/Alcohol for Skin Antisepsis and the Use of Chlorhexidine/Alcohol (ChloraPrep) for Skin Antisepsis: An Open-label, Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
500 (estimated)
Sponsor
Dr. Behcet Uz Children's Hospital · Academic / Other
Sex
All
Age
1 Month – 18 Years
Healthy volunteers
Not accepted

Summary

In this study, blood culture contamination rates will be compared in patients who used povidine/iodine-alcohol and chlorhexidine/alcohol, which were applied before the blood culture was taken by randomized two methods routinely used in this study.

Detailed description

Detection of the pathogen in blood cultures as soon as possible reduces mortality significantly by providing timely initiation of treatment1. However, when skin antisepsis is not performed properly, an increase in the rate of contamination is observed. In this study, it was planned to compare the contamination rate of two antiseptics, povidine iodine/alcohol and Chlorhexidine/alcohol used as skin antisepsis, in the blood culture taken. Full randomization" will be applied in the study. Multiples of 3 of the patients to be included in the study will be included in the "Chloraprep" group, the remaining patients and multiples of 2 will be included in the "povidine/iodine" group. . According to the number of samples determined for each institution, patients who came to the outpatient clinic during data collection and accepted to participate in the study will be randomly selected.

Conditions

Interventions

TypeNameDescription
PROCEDUREdisinfection of the surface that the blood culture is takenlood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.

Timeline

Start date
2023-10-15
Primary completion
2024-11-01
Completion
2024-12-01
First posted
2022-10-12
Last updated
2023-02-01

Source: ClinicalTrials.gov record NCT05576233. Inclusion in this directory is not an endorsement.